Michael C Cameron Selected Research

abrocitinib

8/2022	Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
1/2022	Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).
1/2022	Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
10/2021	Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.
9/2021	Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael C Cameron Research Topics

Disease

5	Atopic Dermatitis (Atopic Eczema) 08/2022 - 09/2021
3	Actinic Keratosis 10/2018 - 01/2016
2	Eczema 01/2022 - 01/2022
2	Basal Cell Carcinoma (Rodent Ulcer) 10/2018 - 03/2018
1	Nausea 01/2022
1	Acne Vulgaris 01/2022
1	Conjunctivitis 01/2022
1	Headache (Headaches) 01/2022
1	Pruritus (Itching) 01/2022
1	Nasopharyngitis 01/2022
1	Pain (Aches) 03/2020
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2018
1	Keratoacanthoma 03/2018
1	Keloid 03/2018
1	Hypertrophic Cicatrix (Hypertrophic Scar) 03/2018
1	Rheumatoid Arthritis 01/2017
1	Dermatitis 01/2016
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016
1	Neoplasms (Cancer) 08/2015
1	Hand-Foot Syndrome 08/2015
1	Stevens-Johnson Syndrome (Lyell's Syndrome) 11/2014
1	Status Epilepticus (Complex Partial Status Epilepticus) 08/2011
1	Temporal Lobe Epilepsy 08/2011

Drug/Important Bio-Agent (IBA)

5	abrocitinibIBA 08/2022 - 09/2021
2	Janus Kinase 1IBA 08/2022 - 10/2021
2	Fluorouracil (Carac)FDA LinkGeneric 10/2018 - 03/2018
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2017 - 11/2014
1	dupilumabIBA 01/2022
1	CytokinesIBA 10/2021
1	Analgesics (Analgesic Drugs)IBA 03/2020
1	Methotrexate (Mexate)FDA LinkGeneric 01/2017
1	Prednisone (Sone)FDA LinkGeneric 01/2017
1	Pemetrexed (MTA)FDA Link 01/2016
1	ErbB Receptors (EGF Receptor)IBA 08/2015
1	Pilocarpine (Ocusert)FDA LinkGeneric 08/2011

Therapy/Procedure

2	Therapeutics 09/2021 - 08/2015
1	Drug Tapering 01/2022
1	Retreatment 01/2022
1	Induction Chemotherapy 01/2016